Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals — Investor Presentation (May 2020)

29 slides from Dicerna Pharmaceuticals's investor presentation, May 8, 2020

  1. Slide 1: Corporate Overview May 2020

    Corporate Overview May 2020 © 2020 DICERNA

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi

  3. Slide 3: Dicerna Vision and Strategy

    Dicerna Vision and Strategy VISION STRATEGY Develop and commercialize our core Maximize the impact high-probability-of-success programs either alone or in collaboration of RNAi on medicine with partners Broadly enable the use of our GalXC™ technology by collaborating with therapeutic area leaders on

  4. Slide 4: Dicerna Pipeline of Core and Collaborative Programs

    Dicerna Pipeline of Core and Collaborative Programs TARGET DISCOVERY/ CLINICAL PROOF-OF- REGISTRATION DICERNA’S CANDIDATE PRECLINICAL INDICATION RESEARCH CONCEPT TRIALS TRIALS PRODUCT RIGHTS Nedosiran Primary 100% (DCR-PHXC) Hyperoxaluria RG6346* Hepatitis B Virus U.S. opt-in Core (DCR-HBVS) Program

  5. Slide 5: The Foundation of Our Value

    The Foundation of Our Value Delivery agents GalXC RNAi trigger • Proprietary, patented RNA interference (RNAi) technology with potential to extend to diverse tissues beyond the liver • Clinically compelling pharmaceutical properties Subcutaneously delivered → convenient administration Long duration

  6. Slide 6: Multiple Upcoming Milestones

    Multiple Upcoming Milestones*  Nedosiran: First multidose results from PHYOX3 open-label clinical trial  Nedosiran: PHYOX2 pivotal clinical trial enrollment completion – timing TBD  RG6346: Phase 1 proof-of-concept data from all existing cohorts – August 2020 R&D Day  GalXC: Present data for ext

  7. Slide 7: Primary Hyperoxaluria

    Primary Hyperoxaluria 7 ©2020 DICERNA

  8. Slide 8: Primary Hyperoxaluria (PH)

    Primary Hyperoxaluria (PH) A family of ultra-rare, life-threatening genetic disorders resulting in renal complications • Three known types of PH, each resulting from a mutation in one Known Types of Primary Hyperoxaluria of three different genes, cause enzyme deficiencies manifesting PH1 PH2 PH3 Gen

  9. Slide 9: PHYOX1: Phase 1 Single-Dose Study of Nedosiran in PH1 and PH2 Participants

    PHYOX1: Phase 1 Single-Dose Study of Nedosiran in PH1 and PH2 Participants 14/18 participants achieved normalization or near-normalization PHYOX1: Mean Urinary Oxalate Levels by Dose* 3.0 PHYOX1 open-label study included: 3.0 mg/kg • ) 6.0 mg/kg • 18 participants dosed: PH1 hr 2.5 (n=15) and PH2 (n=

  10. Slide 10: PHYOX3: Open-Label Multidose Study of Nedosiran

    PHYOX3: Open-Label Multidose Study of Nedosiran Analysis of preliminary interim data in March 2020 • PHYOX3 long-term, multidose, open-label rollover extension trial ongoing - 14* participants enrolled as of preliminary analysis - 4 participants had received at least three monthly doses of nedosiran

  11. Slide 11: Nedosiran Clinical Trial Program to NDA Filing

    Nedosiran Clinical Trial Program to NDA Filing Coordinated program of clinical trials to support a broad label in PH Pivotal Study Package Trial Description/Details Status PH Type Study 201: Pivotal, double-blind, randomized, placebo-controlled Enrolling trial (2:1 randomization) 1,2 n=~36 Monthly f

  12. Slide 12: Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types

    Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types High unmet medical need across all PH types can be addressed Genetics of PH All Known PH1 PH2 PH3 Physician PH Types Patient & Education Caregiver Genetic prevalence 8.23 5.08 12.58 25.89 Support (per million) U.S. 2,681 1,655 4

  13. Slide 13: Chronic Hepatitis B Virus Infection

    Chronic Hepatitis B Virus Infection 13 ©2020 DICERNA

  14. Slide 14: Hepatitis B: A Severe, Global Unmet Medical Need

    Hepatitis B: A Severe, Global Unmet Medical Need • Significant worldwide prevalence: ~292 million infected • Causes more than 887,000 deaths per year • Current treatments are rarely effective in achieving functional cures • Dicerna is collaborating with Roche to develop RG6346 (DCR-HBVS) and potenti

  15. Slide 15: GalXC RNAi May Play a Key Role in Establishing a Functional HBV Cure

    GalXC RNAi May Play a Key Role in Establishing a Functional HBV Cure Organization of the HBV genome enables effective RNAi targeting of multiple viral functions The Promise of RNAi for HBV Overlapping mRNAs and protein-coding regions enable targeting multiple HBV genes and proteins with a single Gal

  16. Slide 16: Single-Dose GalXC-HBVS Reduced HBsAg to Below Lower Level of Detection

    Single-Dose GalXC-HBVS Reduced HBsAg to Below Lower Level of Detection Striking pharmacodynamic differences between targeting in the S alone vs. S and X ORFs in preclinical model HDI-HBV HDI-HBV Plasmid Model Vehicle control • Immunohistochemical (cccDNA-dependent) staining of mouse liver sections f

  17. Slide 17: RG6346 (DCR-HBVS) Clinical Program for Proof of Concept

    RG6346 (DCR-HBVS) Clinical Program for Proof of Concept Includes placebo-controlled studies in both NUC-naïve and NUC-experienced patients Three-Part Study in Healthy Volunteers and Patients With Chronic HBV Infection Placebo-controlled, single-ascending-dose study Completed RG6346 dose cohorts: Gro

  18. Slide 18: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    Alpha-1 Antitrypsin Deficiency- Associated Liver Disease 18 ©2020 DICERNA

  19. Slide 19: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Most disease is caused by a single missense allele that forms aggregates in hepatocytes • Alpha-1 antitrypsin (A1AT): predominantly α1-Antitrypsin Deficiency produced in liver and secreted into blood Z mutation Glu342→Lys342 • Pi*ZZ genotype of

  20. Slide 20: Activity of DCR-A1AT in Mice and Non-Human Primates

    Activity of DCR-A1AT in Mice and Non-Human Primates Potency and duration of action Z-AAT Protein Knockdown in PiZ Mice A1AT Protein Knockdown in Monkeys PBS 3.0 mg/kg 3.0 mg/kg 10.0 mg/kg 10.0 mg/kg SEM SEM ± ± Mean Mean Mean Mean AAT Protein Protein Concentration AAT - Relative A1AT Protein Concent

  21. Slide 21: DCR-A1AT Clinical Program for Proof of Concept

    DCR-A1AT Clinical Program for Proof of Concept Part of larger A1AT clinical plan to achieve a rapid path to approval • Two-part study: Single-ascending-dose (SAD) in healthy volunteers (HVs) and multiple-ascending-dose (MAD) in patients with A1AT deficiency-associated liver disease - HVs: SAD study,

  22. Slide 22: Dicerna-Alnylam Collaboration on A1AT Deficiency-Associated Liver Disease

    Dicerna-Alnylam Collaboration on A1AT Deficiency-Associated Liver Disease Agreement struck to advance candidate(s) with greatest potential to benefit patients • Development and commercialization agreement for A1AT deficiency-associated liver disease in April 2020 − Dicerna takes development responsi

  23. Slide 23: Corporate Collaborations

    Corporate Collaborations 23 ©2020 DICERNA

  24. Slide 24: Enhancing Value Through GalXC Collaboration Strategy

    Enhancing Value Through GalXC Collaboration Strategy Successive collaborations increasing in scope and value $175M upfront $75M total annuals $200M upfront $50M equity • RG6346 (DCR- • 30+ potential HBVS) and multiple targets for liver- potential HBV- related CM diseases $100M upfront related target

  25. Slide 25: Summary

    Summary 25 ©2020 DICERNA Dicerna”

  26. Slide 26: Elements of Portfolio Strategy

    Elements of Portfolio Strategy We seek to generate value across the full spectrum of GalXC clinical applications Core Programs Collaborative Programs Highest Lower Resource Resource Investment Investment Cardiometabolic and Liver-related Diseases • Primary hyperoxaluria Chronic HBV • HBV (U.S. opt-i

  27. Slide 27: Strong Cash Position Provides Runway Through Commercialization

    Strong Cash Position Provides Runway Through Commercialization Additional cash upside expected from collaboration milestones and potential royalties on product sales • Company well capitalized with approximately $706.9 million in unaudited cash, cash equivalents and marketable securities as of March

  28. Slide 28: Multiple Upcoming Milestones

    Multiple Upcoming Milestones*  Nedosiran: First multidose results from PHYOX3 open-label clinical trial  Nedosiran: PHYOX2 pivotal clinical trial enrollment completion – timing TBD  RG6346: Phase 1 proof-of-concept data from all existing cohorts – August 2020 R&D Day  GalXC: Present data for ext

  29. Slide 29: Dicerna

    Dicerna 29 ©2020 DICERNA

Dicerna Pharmaceuticals — Investor Presentation (May 2020) on 6ix